Enough is enough–it is time for Congress to address rising insulin prices. Congress has failed to take any action to address the rising cost of insulin. However, the Protecting Access to Biosimilars Act of 2019, introduced by Rep. Diana DeGette (D-CO) in early April, is a promising first step to address the issue. The Energy […]
Reflections on Binding Arbitration Briefing
As Congress and the Trump Administration consider policies to address rising prescription drug prices, the National Coalition on Health Care (NCHC) hosted a Capitol Hill briefing on March 15th to put one promising option on the table: the use of binding arbitration in Medicare Part D to determine prices for a limited set of drugs. […]
Surprise Medical Billing Legislation: Issues for Congress to Consider
FACT SHEET Legislative solutions are needed to combat the rising cost of health care in the United States, which accounted for almost 18% of the GDP in 2017. One symptom of the problem, surprise medical bills, contributes to unpredictable, high out-of-pocket costs for consumers. Patients often encounter surprise medical bills when receiving emergency or ancillary […]
John Rother’s Orphan Drug Presentation
On April 10th, NCHC President & CEO John Rother presented at the World Orphan Drug Congress 2019 Conference & Expo to discuss potential policy options to address the rising cost of drugs. Mr. Rother discussed proposals from the FDA, HHS, and Congress. Mr. Rother also identified 4 feasible options to address drug affordability. The slides […]
Policy Solutions to Address the Rising Cost of Insulin
Juvenile diabetes is an autoimmune disorder that affects over 1.25 million Americans. Also known as Type 1 diabetes, it occurs when the body stops producing the blood-glucose regulating hormone insulin; thus, juvenile diabetics must receive consistent insulin therapy to survive. Although insulin was discovered in the 1920s, prices for the drug are astronomical by today’s […]
- 1
- 2
- 3
- …
- 9
- Next Page »